The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
5-fluorouracil and cardiotoxicity: a review
Open accessAbstract
Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world. As with all chemotherapy, balancing the potential benefits of therapy against the risks of drug-related toxicity is crucial when clinicians and patients make shared decisions about treatment. 5-FU is the second most common chemotherapeutic drug associated with cardiotoxicity after anthracyclines, which can manifest as chest pain, acute coronary syndrome/myocardial infarction or death. Nevertheless a widespread appreciation of 5-FU-related cardiotoxicity and its implications is lacking amongst clinicians. In this review, we outline the incidence, possible risk factors, and likely pathophysiological mechanisms that may account for 5-FU-related cardiotoxicity and also highlight potential management strategies for this poorly understood clinical entity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Endothelial Dysfunction: A Marker of Atherosclerotic Risk
Bonetti, P. O., Lerman, L. O., & Lerman, A. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000051384.43104.fc · Cited by 2,200
Self-citationLong-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., & Lerman, A. (2000) · Circulation · doi:10.1161/01.cir.101.9.948 · Cited by 2,043
Self-citationCoronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
Vita, J. A., Treasure, C. B., Nabel, E. G., McLenachan, J. M., Fish, R. D., Yeung, A. C., Vekshtein, V. I., Selwyn, A. P., & Ganz, P. (1990) · Circulation · doi:10.1161/01.cir.81.2.491 · Cited by 1,173
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 960
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4539 · Cited by 656
Pyke, K. E., & Tschakovsky, M. E. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.089755 · Cited by 614
Sara, J. D., Widmer, R. J., Matsuzawa, Y., Lennon, R. J., Lerman, L. O., & Lerman, A. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.06.017 · Cited by 514
Self-citationDiasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
Reddy, K. G., Nair, R. N., Sheehan, H. M., & Hodgson, J. M. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90627-0 · Cited by 447
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
Koizumi, W., Kurihara, M., Nakano, S., & Hasegawa, K. (2000) · Oncology · doi:10.1159/000012099 · Cited by 440
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Coronary Endothelial Dysfunction in Humans Is Associated With Myocardial Perfusion Defects
Hasdai, D., Gibbons, R. J., Holmes, D. R., Higano, S. T., & Lerman, A. (1997) · Circulation · doi:10.1161/01.cir.96.10.3390 · Cited by 398
Self-citationBlum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., & Mayer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5686 · Cited by 391
Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys.
Heistad, D. D., Armstrong, M. L., Marcus, M. L., Piegors, D. J., & Mark, A. L. (1984) · Circulation Research · doi:10.1161/01.res.54.6.711 · Cited by 367
Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen, D. L. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.005 · Cited by 329
Schalkwijk, C. G., Poland, D. C. W., van Dijk, W., Kok, A., Emeis, J. J., Dräger, A. M., Doni, A., van Hinsbergh, V. W. M., & Stehouwer, C. D. A. (1999) · Diabetologia · doi:10.1007/s001250051162 · Cited by 309
2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Supersensitivity of Atherosclerotic Rabbit Aorta to Ergonovine
Henry, P. D., & Yokoyama, M. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109858 · Cited by 258
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Jensen, S. A., & Sørensen, J. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0178-1 · Cited by 232
The pharmacology of the fluoropyrimidines.
Myers, C. E. (1981) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06848-6 · Cited by 191
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.
Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.509 · Cited by 187
Cardiotoxicity of the Antiproliferative Compound Fluorouracil
Becker, K., Erckenbrecht, J. F., aussinger, D. H., & Frieling, T. (1999) · Drugs · doi:10.2165/00003495-199957040-00003 · Cited by 172
5-Fluorouracil induces arterial vasocontractions
Südhoff, T., Enderle, M.-D., Pahlke, M., Petz, C., Teschendorf, C., Graeven, U., & Schmiegel, W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh150 · Cited by 168
Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil
Meyer, C. C., Calis, K. A., Burke, L. B., Walawander, C. A., & Grasela, T. H. (1997) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03748.x · Cited by 162
5-Fluorouracil cardiotoxicity.
Lomeo, A. M., Avolio, C., Iacobellis, G., & Manzione, L. (1990) · PubMed · Cited by 157
Lee, J.-L., Kang, Y.-K., Kang, H. J., Lee, K.-H., Zang, D. Y., Ryoo, B.-Y., Kim, J. G., Park, S. R., Kang, W. K., Shin, D. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604536 · Cited by 134
Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina
Stewart, T. V., Pavlakis, N., & Ward, M. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02144.x · Cited by 132
Anand, A. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800314 · Cited by 132
5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress
Lamberti, M., Porto, S., Marra, M., Zappavigna, S., Grimaldi, A., Feola, D., Pesce, D., Naviglio, S., Spina, A., Sannolo, N., et al. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-60 · Cited by 128
Ma, W. W., Saif, M. W., El‐Rayes, B. F., Fakih, M., Cartwright, T. H., Posey, J. A., King, T. R., von Borstel, R. W., & Bamat, M. K. (2016) · Cancer · doi:10.1002/cncr.30321 · Cited by 125
Cardiotoxic Effects of 5-Fluorouracil in the Guinea Pig
Matsubara, I., Kamiya, J., & Imai, S. (1980) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)52945-6 · Cited by 121
Clinical Cardiotoxicity of 5‐Fluorouracil
Keefe, D. L., Roistacher, N., & Pierri, M. K. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb01943.x · Cited by 104
Prinzmetal's angina during 5-fluorouracil chemotherapy
Kleiman, N. S., Lehane, D. E., Geyer, C. E., Pratt, C. M., & Young, J. B. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90465-7 · Cited by 103
High Incidence of Angina pectoris in Patients Treated with 5-Fluorouracil
Wacker, A., Lersch, C., Scherpinski, U., Reindl, L., & Seyfarth, M. (2003) · Oncology · doi:10.1159/000072334 · Cited by 103
Jensen, S. A., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1669-x · Cited by 100
Maring, J. G., Kuilenburg, A. B. P., Haasjes, J., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600208 · Cited by 99
Cardiac lesions induced by 5-fluorouracil in the rabbit
Tsibiribi, P., Bui-Xuan, C., Bui‐Xuan, B., Lombard‐Bohas, C., Duperret, S., Belkhiria, M., Tabib, A., Maujean, G., Descotes, J., & Timour, Q. (2006) · Human & Experimental Toxicology · doi:10.1191/0960327106ht628oa · Cited by 89
Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk
Lestuzzi, C., Vaccher, E., Talamini, R., Lleshi, A., Meneguzzo, N., Viel, E., Scalone, S., Tartuferi, L., Buonadonna, A., Ejiofor, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu055 · Cited by 89
5-Fluorouracil–Induced Coronary Vasospasm
Shoemaker, L. K., Arora, U. K., & Lima, C. M. R. (2004) · Cancer Control · doi:10.1177/107327480401100107 · Cited by 85
The endothelial cell in health and disease: its function, dysfunction, measurement and therapy
Schwartz, B. G., Economides, C., Mayeda, G. S., Burstein, S., & Kloner, R. A. (2009) · International Journal of Impotence Research · doi:10.1038/ijir.2009.59 · Cited by 84
López, J. A. G., Armstrong, M. L., Piegors, D. J., & Heistad, D. D. (1989) · Circulation · doi:10.1161/01.cir.79.3.698 · Cited by 82
Takotsubo Cardiomyopathy and Fluorouracil: Case Report and Review of the Literature
Grunwald, M. R., Howie, L. J., & Diaz, L. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5278 · Cited by 81
Hasdai, D., Holmes, D. R., Higano, S. T., Burnett, J. C. J., & Lerman, A. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.12.1133 · Cited by 80
Self-citationArellano, M., Malet‐Martino, M., Martino, R., & Gires, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.12 · Cited by 75
Dyhl-Polk, A., Shahmarvand, N., Vistisen, K. K., Vaage‐Nilsen, M., Larsen, F. O., Schou, M., & Nielsen, D. L. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012798 · Cited by 72
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
Nagashima, F., Ohtsu, A., Yoshida, S., & Ito, K. (2005) · Gastric Cancer · doi:10.1007/s10120-004-0306-3 · Cited by 69
5‐Fluorouracil—Induced Tako‐Tsubo—Like Syndrome
Basselin, C., Fontanges, T., Descotes, J., Chevalier, P., Bui‐Xuan, B., Feinard, G., & Timour, Q. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.2.226 · Cited by 67
Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm
Clasen, S. C., Ky, B., O’Quinn, R. P., Giantonio, B. J., Teitelbaum, U., & Carver, J. R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.09.07 · Cited by 63
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Sasson, Z., Morgan, C., Wang, B., Thomas, G., MacKenzie, B. R., & Platts, M. E. (1994) · PubMed · Cited by 52
Yılmaz, U., Öztop, İ., Ciloglu, A., Okan, T., Tekin, Ü. İ., Yaren, A., Somali, I., Alacacıoğlu, A., & Kırımlı, Ö. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01323.x · Cited by 50
Reriani, M., Sara, J. D. S., Flammer, A. J., Gulati, R., Li, J., Rihal, C. S., Lennon, R. J., Lerman, L. O., & Lerman, A. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000347 · Cited by 46
Self-citation5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine
Muneoka, K., Shirai, Y., Yokoyama, N., Wakai, T., & Hatakeyama, K. (2005) · International Journal of Clinical Oncology · doi:10.1007/s10147-005-0516-7 · Cited by 45
Restoring the Dysfunctional Endothelium
Osto, E., Coppolino, G., Volpe, M., & Cosentino, F. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780487566 · Cited by 42
Shahrokni, A., Rajebi, M. R., & Saif, M. W. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.039 · Cited by 41
A Case of 5-Fluorouracil Cardiotoxicity Simulating Acute Myocardial Infarction.
Mizuno, Y., Hokamura, Y., Kimura, T., Kimura, Y., Kaikita, K., & Yasue, H. (1995) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.59.303 · Cited by 32
Bozkurt, O., Karaca, H., Çiltaş, A., Ma, K., Beneklı, M., Sevinç, A., Demırcı, U., Eren, T., Kodaz, H., Işıkdoğan, A., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.4.1845 · Cited by 7
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationAdverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Self-citationLyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationTargeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 271
Engineered nanoparticles for imaging and drug delivery in colorectal cancer
Pavitra, E., Dariya, B., Srivani, G., Kang, S.-M., Alam, A., Sudhir, P.-R., Kamal, M. A., Raju, G. S. R., Han, Y.-K., Lakkakula, B. V. K. S., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.017 · Cited by 102
Metadata
- Authors
- Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2018-01
- Volume
- 10
- Pages
- 1758835918780140-1758835918780140
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2808800848
- Cited by
- 433
- References
- 63
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.